Form 4: Cullinan Therapeutics CMO Sells Shares for Tax
Insider Transaction Report
Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, sold 4,632 shares of common stock at $9.67 per share to cover personal income tax obligations.
Summary
- Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, Inc. (CGEM), reported a transaction involving the company's common stock.
- The transaction occurred on December 18, 2025.
- Jones disposed of 4,632 shares of common stock at a price of $9.67 per share.
- The sale was conducted to cover personal income tax obligations arising from the vesting of restricted stock units.
- Following this transaction, Jones beneficially owns 169,532 shares of common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine sale of shares to cover tax obligations upon RSU vesting, which is a common occurrence for executives and generally considered neutral in terms of company performance or outlook.
Positives
- The sale was triggered by the vesting of restricted stock units, indicating that previously granted equity compensation has matured for the executive.
Negatives
- The Chief Medical Officer reduced his direct beneficial ownership in the company by 4,632 shares.
Risks
- No specific risks were mentioned in this Form 4 filing.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitor analysis.
Stakeholder Impact
- Shareholders: A minor reduction in insider ownership, which is a common event for executives managing equity compensation.
Next Steps
- This Form 4 filing does not mention any specific future actions, events, or milestones for the company.
Key Dates
| Date | Description |
|---|---|
| 12/18/2025 | Date of transaction (sale of common stock) |
| 12/19/2025 | Date Form 4 was signed by Attorney-in-Fact |
Keywords
Cullinan Therapeutics, CGEM, Insider Trading, Form 4, Jeffrey Alan Jones, Chief Medical Officer, Stock Sale, Restricted Stock Units, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.